Compass Therapeutics Ownership
| CMPX Stock | USD 2.10 0.01 0.48% |
Shares in Circulation | First Issued 2018-06-30 | Previous Quarter 137.8 M | Current Value 138.3 M | Avarage Shares Outstanding 82.5 M | Quarterly Volatility 44.3 M |
Compass Stock Ownership Analysis
About 20.0% of the company shares are held by company insiders. The book value of Compass Therapeutics was currently reported as 0.8. The company recorded a loss per share of 0.4. Compass Therapeutics had not issued any dividends in recent years. Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Compass Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. For more info on Compass Therapeutics please contact the company at 617 500 8099 or go to https://www.compasstherapeutics.com.Besides selling stocks to institutional investors, Compass Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Compass Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Compass Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Compass Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Compass Therapeutics Insider Trades History
About 20.0% of Compass Therapeutics are currently held by insiders. Unlike Compass Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Compass Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Compass Therapeutics' insider trades
Compass Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Compass Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Compass Therapeutics backward and forwards among themselves. Compass Therapeutics' institutional investor refers to the entity that pools money to purchase Compass Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blue Owl Capital Holdings Lp | 2025-03-31 | 3 M | Geode Capital Management, Llc | 2025-03-31 | 2.4 M | Jpmorgan Chase & Co | 2025-03-31 | 2.2 M | State Street Corp | 2025-03-31 | 1.9 M | Sg Americas Securities, Llc | 2025-03-31 | 940.8 K | Silverarc Capital Management, Llc | 2025-03-31 | 874.9 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 839.2 K | Northern Trust Corp | 2024-12-31 | 801.2 K | Macquarie Group Ltd | 2025-03-31 | 681.5 K | Orbimed Advisors, Llc | 2025-03-31 | 22.4 M | Tang Capital Management Llc | 2025-03-31 | 11.1 M |
Compass Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Compass Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Compass Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Compass Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Compass Therapeutics Outstanding Bonds
Compass Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Compass Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Compass bonds can be classified according to their maturity, which is the date when Compass Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US20451RAC60 Corp BondUS20451RAC60 | View | |
| US20451RAB87 Corp BondUS20451RAB87 | View | |
| Compass Minerals International Corp BondUS20451NAG60 | View |
Compass Therapeutics Corporate Filings
F4 | 27th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 15th of May 2025 Other Reports | ViewVerify | |
8K | 8th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 29th of April 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.